Quest Diagnostics Inc vs FirstEnergy Corp. — how do they compare? Quest Diagnostics Inc trades at $237.73 (market cap $26.21B), while FirstEnergy Corp. trades at $46.88 (market cap $27.10B). The key difference: Quest Diagnostics Inc and FirstEnergy Corp. are close in size by market cap, and FirstEnergy Corp. pays the higher dividend (3.97%). Which is the better fit depends on your goals.
| DGX | FE | |
|---|---|---|
Market Cap | $26.21B | $27.10B |
Sector | Health | Utilities |
52-Week High | $238.50 | $51.91 |
52-Week Low | $173.49 | $42.83 |
Enterprise Value | $31.97B | $56.02B |
Dividend Yield | 1.45% | 3.97% |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.
DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.
FirstEnergy (FE) trades at $46.76, down 1.5% with bearish technical signals despite recent earnings beat. The utility shows steady revenue growth to $15.09B (2025) and maintains a 6.86% net margin, though EPS performance has been mixed. Analyst consensus is divided with 12 Buy and 16 Hold ratings, targeting $52.67 average price. Recent news highlights institutional buying and grid investments to support rising data center demand.
Investment outlook balances growth from infrastructure spending and data center demand against execution risks and debt levels. The stock offers value below analyst targets with dividend income, but faces headwinds from capital expenditure requirements and interest rate sensitivity. Current valuation at P/E 25.05 appears reasonable for sector growth prospects.
Trailing returns across standard periods
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →FirstEnergy is one of the largest investor-owned utilities in the United States with 10 regulated distribution companies across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems with 24,000 miles of lines.
Read more on FE →